Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche is all set to expand its collaboration with Aileron Therapeutics to discover, develop and commercialize stapled peptide drugs.
Subscribe to our email newsletter
The companies entered the $1.1bn collaboration agreement in August 2010, which covers five programs.
Under the collaboration, the two key programs were pertaining to oncology and the third program will commence on inflammatory diseases.
In addition, Aileron is said to have reached key research milestone for strategic oncology program.
The financial details of the agreement and milestone payment have not been revealed.
Aileron president and CEO Joseph A Yanchik said their Stapled Peptide drugs are capable of addressing targets, in manner and effect, that have eluded small molecules and antibodies.
"Given the potential impact of this technology and the associated scrutiny, it was essential for us to set a high bar and show early success with a partnered drug discovery program," Yanchik added.